Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: A randomized clinical trial

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Bethell, Delia ^a   Se, Youry ^a   Lon, Chanthap ^a   Tyner, Stuart ^a   Saunders, David ^a   Sriwichai, Sabaithip ^a   Darapiseth, Sea ^b   Teja Isavadharm, Paktiya ^a   Khemawoot, Phisit ^a   Schaecher, Kurt ^a   Ruttvisutinunt, Wiriya ^a   Lin, Jessica ^a   Kuntawungin, Worachet ^a   Gosi, Panita ^a   Timmermans, Ans ^a   Smith, Bryan ^a   Socheat, Duong ^b   Fukuda, Mark M ^a  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b Center for Parasitology Entomology and Malaria Control   (Cambodia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISIN; ARTESUNATE; CHLOROQUINE; DIHYDROARTEMISININ; MEFLOQUINE; ANTIAMEBIC AGENT; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ADULT; ANTIMALARIAL DRUG RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CAMBODIA; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PARASITE CLEARANCE; PHENOTYPE; PLASMODIUM FALCIPARUM; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG RESISTANCE; MALARIA; MAXIMUM TOLERATED DOSE; PARASITEMIA;

ARTESUNATE; PLASMODIUM FALCIPARUM;

ADOLESCENT; ADULT; AMEBICIDES; ANTIMALARIALS; ARTEMISININS; CAMBODIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HUMANS; MALARIA; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PARASITEMIA; YOUNG ADULT;

EID: 79955942990     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019283     Document Type: Article

References (25)

1. Wongsrichanalai C, Meshnick SR, (2008) Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerging Infectious Diseases 14: 716-719.
2. Enserink M, (2010) Malaria's drug miracle in danger. Science pp. 844-846.
3. White NJ, (2010) Artemisinin resistance- the clock is ticking. 376: 2051-2052.
4. WHO, (2010) Global Report on Antimalarial Drug Efficacy and Drug Resistance: 2000-2010. Geneva WHO.
5. Anderson TJ, Nair S, Nkhoma S, Williams JT, Imwong M, et al. (2010) High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in Cambodia. J Infect Dis 201: 1326-1330.
6. Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes K, et al. (2010) In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 201: 570-578.
7. Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, et al. (2010) Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in southeast Asia. Clin Infect Dis 51: e82-e89.
8. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455-467.
9. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, et al. (2008) Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359: 2619-2620.
10. WHO, (2000) Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 94 (Suppl 1): S1-90.
11. British Pharmacopoeia (1998) Uniformity of Weight (Mass), Ph Eur Method 2.9.5. Appendix XII G.
12. British Pharmacopoeia (1998) Uniformity of Content, Ph Eur Method 2.9.6. Appendix XII H.
13. WHO (2009) Methods for Surveillance of Antimalarial Drug Efficacy. Geneva World Health Organization.
14. Teja-Isavadharm P, Siriyanonda D, Siripokasupkul R, Apinan R, Chanarat N, et al. (2010) A simplified liquid chromoatography-mass spectrometry assay for artesunate and dihydroartemisinin, its metabolite, in human plasma. Molecules (in press).
15. Noedl H, Teja-Isavadharm P, Miller RS, (2004) Nonisotopic, semiautomated Plasmodium falciparum bioassay for measurement of antimalarial drug levels in serum or plasma. Antimicrob Agents Chemother 48: 4485-4487.
16. Noedl H, Attlmayr B, Wernsdorfer WH, Kollaritsch H, Miller RS, (2004) A histidine-rich protein 2-based malaria drug sensitivity assay for field use. Am J Trop Med Hyg 71: 711-714.
17. Trager W, Jensen JB, (1976) Human malaria parasites in continuous culture. Science 193: 673-675.
18. Snounou G, Xinping Z, Napaporn S, Jarra W, Thaithong S, et al. (1999) Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg 93: 369-374.
19. Snounou G, Beck HP, (1998) The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol Today 14: 462-467.
20. Schulz KF AD, Moher D, (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 340: 698-702.
21. Bethell DB, Se Y, Lon C, Socheat D, Saunders D, et al. (2010) Dose-dependant risk of neutropenia following 7-day courses of artesunate monotherapy in Cambodian patients with acute P. falciparum malaria. Clin Infect Dis 51: e105-e114.
22. Borrmann S, Matsiegui PB, Missinou MA, Kremsner PG, (2008) Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children. Antimicrob Agents Chemother 52: 1799-1805.
23. Druihle P, Daubersies P, Patarapotikul J, Gentil C, Chene L, et al. (1998) A primary malarial infection is composed of a very wide range of genetically diverse but related parasites. j Clin Invest 101: 2008-2016.
24. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, et al. (2009) Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J 8: 253.
25. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, et al. (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181.